Frankel Stanley 4

What Happened

• Stanley Frankel, a director of Precision BioSciences, was awarded 20,979 restricted stock units (RSUs) on June 3, 2026. The RSUs were granted at $0.00 (no cash paid) and therefore have a reported transaction value of $0 on the Form 4.
• This is an equity award (grant), not an open-market buy or sale. Grants are typically compensation or retention awards and do not by themselves indicate buying or selling sentiment.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (appears timely).
• Grant: 20,979 RSUs at $0.00 (derivative security). Reported as an "A" (award/grant).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes from the filing:
  • Each RSU represents a contingent right to receive one share of common stock (F1).
  • Vesting: RSUs vest on the earlier of (i) June 3, 2027 or (ii) the day before the issuer’s next annual meeting following the grant date, subject to continued service (F2).

Context

• RSUs are a form of deferred equity compensation; the recipient generally receives shares only if vesting conditions (here, continued service and the date conditions) are met.
• Because this was a grant rather than a purchase or sale, it’s primarily a compensation/retention event and not a direct signal of insider buying or selling.